ASTERIAS BIOTHERAPEUTICS, INC. filed this 425 on 20190124

Document Outline
Entire Document (45 KB)
Subdocument - 425 - 425
  Page 1 - Asterias Provides Top Line 12 Month Data Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spi
  Page 2 - OPC1 Therapeutic Platform
  Page 3 - About OPC1
  Page 4 - FORWARD-LOOKING STATEMENTS
  Page 5 - Participants in the Solicitation